论文部分内容阅读
迎战WTO,是今年两会的热门话题。当谈到“入世”将对国内中药企业有何冲击时,人大代表、敖东药业总裁李秀林沉思了一下说:“对有备者来说,冲击不大;对无备者而言,冲击将很大。”“你们敖东准备得怎么样了?”记者问道。“不仅有准备了,而且我们已有了走出国门的5年经历。”李秀林轻松地说。“1996年,我们的主打产品‘安神补脑液’作为国内中药产品第一个通过了美国FDA质量认证,并第一个打入美国市场。不出国门不知道,出了国门吓一跳。我们有着安全、标本兼治优势的中药制品,到了国外,它自身的不定量定
Against the WTO, this year’s two sessions a hot topic. When it comes to what impact China’s accession to the WTO will have on domestic Chinese medicine companies, Li Xiu-lin, deputies to the Aodong Pharmaceutical Industry, pondered for a moment, saying: Words, the impact will be great. ”“ How are you Aodong prepared? ”Reporter asked. “Not only are we ready, but we have a five-year experience of going abroad.” Li Xiu-lin said easily. “In 1996, our flagship product,” soothe the nerves Bunao fluid "as the first Chinese traditional Chinese medicine products passed the FDA quality certification, and the first into the United States market. Do not go abroad do not know, out of the country scared We have the safety, the advantages of both the traditional Chinese medicine products, to a foreign country, its own set of quantitative